Elizabeth Uhlenhake, MD

Dr. Uhlenhake is a dual board certified dermatologist and dermatopathologist. She is a fellow with the American Academy of Dermatology and the American Society of Dermatopathology. She joined The Dermatology Group in 2017 and has experience in providing high quality medical and surgical dermatology care for patients in addition to producing accurate and clinically focused dermatopathology reports. Patients are her priority and she goes to great lengths to ensure the best, most efficient patient care is provided to all.

Education

• Undergraduate Degree: Bachelor of Science, Kent State University
• Medical Degree: Northeast Ohio Medical University (Northeastern Ohio Universities College of Medicine)

Internship, Residency and Fellowship

• Internship in Internal Medicine: Kettering Medical Center, Dayton, Ohio
• Dermatology Residency: Wayne State University, Detroit, Michigan
• Dermatopathology Fellowship: University of Arkansas Medical Sciences, Little Rock, Arkansas

Honors and Associations

• 2014 Bruce R. Smoller Pathology Resident & Fellow Research Symposium Research Award
• 2013 Women’s Dermatologic Society Mentorship Award
• 2009 North American Primary Care Research Award for Outstanding Primary Care Research
• 2008 Ohio Academy of Family Physicians Best Research Presentation
• 2007 Women’s Dermatologic Society Medical Student Awareness Award
• 2007 Life Banc Organ Donation Student Volunteer of the Year - Summa Cum Laude, Kent State University
• Member of the AAD (American Academy of Dermatology), ASDP (American Society of Dermatopathology), and American Medical Association (AMA)

Publications

• Uhlenhake E, Smoller B, Shalin S, Gardner J. Characterization of Dermatopathology Fellow Applicants: a Five-Year Experience. Journal of Cutaneous Pathology. 2016;43:411-7.
• Uhlenhake E, Smoller B, Shalin S, Gardner J. Nuclear factor XIIIa staining (clone AC-1A1 mouse monoclonal) is a sensitive and specific marker to discriminate sebaceous proliferations from other cutaneous clear cell neoplasms. Journal of Cutaneous Pathology. 2016;43:649-56.
• Clark L, Elwood H, Uhlenhake E, Smoller B, Shalin S, Gardner J. Nuclear factor XIIIa staining (clone AC-1A1 mouse monoclonal) is a highly sensitive marker of sebaceous differentiation in normal and neoplastic sebocytes. Journal of Cutaneous Pathology. 2016;43:657-62.
• Uhlenhake E, Smoller B, Shalin S, Gardner J. Epithelioid melanocytic nevus with pseudoacini formation. Journal of Cutaneous Pathology. Journal of Cutaneous Pathology. 2015;42:213-16.
• Uhlenhake E, Gokden M, Gardner J. An Infantile Scalp Mass: Cranial Fasciitis. American Society of Dermatopathology On-line Case of the month- September 2014.
• Uhlenhake E, Murrell D. Drugs Eruptions: 20 Years of Dermatology Practice. Australian Doctor. 2013;22:33-35.
• Uhlenhake E, Aronson P, Watson A. Sorafenib Induced Eruptive Melanocytic Lesions. Dermatology Online Journal. 2013;19:13.
• Uhlenhake E. Optimal treatment of actinic keratoses. Journal Clinical Interventions in Aging. 2013;8:29-35.
• Uhlenhake E, Mehregan DR. A Prospective Examination of Histologic Findings in Patients who Practice Traumatic Hairstyling. International Journal of Dermatology. 2013:52,:1506–12.
• Uhlenhake E, Mehregan DA. Managing Psoriasis: What’s Best for your Patient. Journal of Family Practice. 2012:61:402-51.
• Uhlenhake E, Mehregan DR. Annular Hypopigmented Mycosis Fungoides: A Novel Ringed Variant. Journal of Cutaneous Pathology. 2012;39:535-539.
• Uhlenhake E, Feldman S. Psoriasis Patient-Physician Interactions. Psoriasis Forum. 2011;17:1-5.
• Uhlenhake E, Mehregan DA. Ustekinumab- Differential Use in Psoriasis. Clinical, Cosmetic, and Investigational Dermatology. 2011;4:93–99.
• Uhlenhake E, Sangueza O, Jorizzo J. Spreading Pigmented Actinic Keratosis: A Review. Journal of the American Academy of Dermatology. 2010;63:499-506.
• Uhlenhake E, Feldman S. Efficacy and Safety of Ustekinumab and Etanercept for the Treatment of Psoriasis. Expert Opinion On Biological Therapy. 2010;10:1105-1112.
• Uhlenhake E, Yentzer B, Feldman S. Acne vulgaris and depression: a retrospective examination. Journal of Cosmetic Dermatology. 2010;9:59–63.
• Uhlenhake E, Feldman S. Dermatological Safety: Problems and Solutions. Journal of Dermatological Treatment. 2010;21:86-92.
• Uhlenhake E, Kurkowski D, Feldman S. Conversations on Psoriasis- What Patients Want and What Physicians Can Provide: A Qualitative Look at Patient and Physician Expectations. Journal of Dermatological Treatment. 2010;21:6-12.
• Uhlenhake E, Bhatia A. Photography of Skin Malignancies Post Laser Treatments. Lasers in Dermatology and Medicine First Edition. Editor Keyvan Nouri, 2009, Springer, London
• Uhlenhake E, Bhatia A. Online Resources for Dermatological Laser Therapies. Lasers in Dermatology and Medicine First Edition. Editor Keyvan Nouri, 2009, Springer, London
• Uhlenhake E, Brodell R, Nedorost S. Pruritic rash. Journal of Family Practice. 2009;58:597-600.
• Uhlenhake E, Brodell R, Mostow E. The Dermatology Work Force: A Focus on Urban versus Rural Wait Times. Journal of the American Academy of Dermatology. 2009; 61:17-22.
• Uhlenhake E, Davidson E, McCord G. Increasing Lipid Adherence to Goal. The Journal of Clinical Lipidology. 2008;2:354-59.

Dr. Uhlenhake sees patients at the following locations: Mason, OH